Epigenetic Reader Domain
All Product Categories
-
Epigenetic Reader Domain Inhibitors
(328)
View all products
-
Epigenetic Reader Domain Agonists
(2)
View all products
-
Epigenetic Reader Domain Antagonists
(2)
View all products
-
Epigenetic Reader Domain Activators
(3)
View all products
-
Epigenetic Reader Domain Modulators
(2)
View all products
-
Epigenetic Reader Domain Chemicals
(2)
View all products
-
Epigenetic Reader Domain Degraders
(32)
View all products
-
Epigenetic Reader Domain Controls
(11)
View all products
-
Epigenetic Reader Domain Substrate
(1)
View all products
-
Epigenetic Reader Domain Ligands
(3)
View all products
-
Epigenetic Reader Domain Related Products (433)
Related Products (433)
-
Revumenib
0 ImagesSynonyms: SNDX-5613Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
-
5-Ph-IAA
0 Images5-Ph-IAA is a derivative of IAA. 5-Ph-IAA, a ligand, establishes the auxin-inducible degron 2 (AID2) system together with an OsTIR1 (F74G) mutant. AID2 induces rapid and efficient depletion of mAID-fused proteins to study protein function in living cells, causing tumor suppression.
-
Enzomenib enantiomer
0 ImagesCat. No.: HY-156794APurity: 98.01%Synonyms: DSP-5336 enantiomerEnzomenib enantiomer (DSP-5336 enantiomer) is an enantiomer of Enzomenib (HY-156794). Enzomenib (DSP-5336) is an orally active Menin inhibitor (IC50=1.4 nM, Kd=6.0 nM). Enzomenib disrupts the interaction between Menin and KMT2A/MLL fusion proteins, specifically inhibits the expression of leukemia driver genes such as HOX/MEIS1, and upregulates ITGAM. Enzomenib effectively induces cell differentiation, inhibits tumor cell proliferation, and suppresses primitive cell colony formation. Enzomenib reduces disease burden and prolongs survival, but causes adverse reactions including differentiation syndrome and QTc interval prolongation. Enzomenib is used for research on relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, and other hematologic malignancies with mixed lineage leukemia (MLL) rearrangements or NPM1 mutations.
-
cis-Revumenib
0 ImagesCat. No.: HY-136175BPurity: 98.92%Synonyms: cis-SNDX-5613cis-Revumenib (cis-SNDX-5613) is an isomer of Revumenib (HY-136175). Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
-
VTP50469
0 ImagesSynonyms: SNDX-50469VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity.
-
Birabresib
0 ImagesSynonyms: OTX-015; MK-8628Birabresib (OTX-015) is a potent bromodomain (BRD2/3/4) inhibitor with IC50s ranging from 92 to 112 nM.
-
Ziftomenib
0 ImagesSynonyms: KO-539Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).
-
I-BET151
0 ImagesSynonyms: GSK1210151AI-BET151 (GSK1210151A) is a BET bromodomain inhibitor which inhibits BRD4, BRD2, and BRD3 with pIC50 of 6.1, 6.3, and 6.6, respectively.
-
KG-501
0 ImagesSynonyms: Naphthol AS-E phosphateKG-501 is a CREB inhibitor, with an IC50 of 6.89 μM.
-
Molibresib
0 ImagesSynonyms: I-BET762; GSK525762; GSK525762AMolibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC50 of 32.5-42.5 nM.
-
GNE-781
0 ImagesGNE-781 is an orally active, highly potent and selective CBP inhibitor with an IC50 of 0.94 nM in TR-FRET assay. GNE-781 also inhibits BRET and BRD4(1) with IC50s of 6.2 nM and 5100 nM, respectively. GNE-781 displays antitumor activity in an MOLM-16 AML xenograft model.
-
Apabetalone
0 ImagesSynonyms: RVX-208; RVX000222Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87 μM and 0.51 μM for BD1 and BD2, respectively.
-
BAY-850
0 ImagesBAY-850, a chemical probe, is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM.
-
PI3K/Akt/CREB activator 1
0 ImagesPI3K/Akt/CREB activator 1 (compound AE-18) is a potent, orally active PI3K/Akt/CREB activator. PI3K/Akt/CREB activator 1 promotes neuronal proliferation, induced differentiation of Neuro-2a cells into a neuron-like morphology, and accelerated the establishment of axon-dendrite polarization of primary hippocampal neurons through upregulating brain-derived neurotrophic factor via the PI3K/Akt/CREB pathway. PI3K/Akt/CREB activator 1 can be used in research of vascular dementia (VaD).
